VWF and von Willebrand disease type 2B: Fourth, platelet-VWF binding did not diminish with agonist-induced platelet-fibrinogen binding (Fig 4D), disproving our hypothesis that increased platelet-VWF binding underlies the inhibition of the platelet αIIbβ3 signaling pathway, as recently reported for von Willebrand disease type 2B [15].